Treatment of fungal infections in patients with hematologic neoplasia;Tratamiento de las infecciones fúngicas en pacientes con neoplasias hematológicas

Medicina Clinica

Volumn 132, Issue 13, 2009, Pages 507-521

  Mensa, José ^a   De La Cámara, Rafael ^b   Carreras, Enric ^b   Cuenca Estrella, Manuel ^a   García Rodríguez, José Ángel ^a   Gobernado, Miguel ^a   Picazo, Juan ^a   Aguado, José María ^a   Sanz, Miguel Ángel ^b  

^a Sociedad Española de Quimioterapia SEQ   (Spain)

^b Asociación Madrileña de Hematologiá y Hemoterapia AMHH   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; MYCOGRAB; POSACONAZOLE; VORICONAZOLE;

ARTICLE; ASPERGILLOSIS; BLOOD DISEASE; BLOOD TOXICITY; CENTRAL VENOUS CATHETER; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; MYCOSIS; NEUTROPENIA; RECOMMENDED DRUG DOSE;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; HEMATOLOGIC NEOPLASMS; HUMANS; MYCOSES;

EID: 64649093268     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2009.01.008     Document Type: Article

References (188)

1. [Prophylaxis and treatment of fungal infections in oncohematological patients]. Rev Esp Quimioter. 2002;15:387-401.
2. Gross P.A., Barrett T.L., Dellinger E.P., Krause P.J., Martone W.J., McGowan Jr. J.E., et al. Purpose of quality standards for infectious diseases. Infectious Diseases Society of America. Clin Infect Dis 18 (1994) 421
3. Villanueva A., Arathoon E.G., Gotuzzo E., Berman R.S., DiNubile M.J., and Sable C.A. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 33 (2001) 1529-1535
4. Arathoon E.G., Gotuzzo E., Noriega L.M., Berman R.S., DiNubile M.J., and Sable C.A. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 46 (2002) 451-457
5. Villanueva A., Gotuzzo E., Arathoon E.G., Noriega L.M., Kartsonis N.A., Lupinacci R.J., et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 113 (2002) 294-299
6. De Wet N.T., Bester A.J., Viljoen J.J., Filho F., Suleiman J.M., Ticona E., et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 21 (2005) 899-907
7. Krause D.S., Simjee A.E., Van Rensburg C., Viljoen J., Walsh T.J., Goldstein B.P., et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 39 (2004) 770-775
8. Pfaller M.A., Diekema D.J., Boyken L., Messer S.A., Tendolkar S., Hollis R.J., et al. Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. Antimicrob Agents Chemother 49 (2005) 4795-4797
9. Ally R., Schurmann D., Kreisel W., Carosi G., Aguirrebengoa K., DuPont B., et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 33 (2001) 1447-1454
10. Vázquez J.A., Skiest D.J., Nieto L., Northland R., Sanne I., Gogate J., et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 42 (2006) 1179-1186
11. Kartsonis N., DiNubile M.J., Bartizal K., Hicks P.S., Ryan D., and Sable C.A. Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J Acquir Immune Defic Syndr 31 (2002) 183-187
12. Hegener P., Troke P.F., Fatkenheuer G., Diehl V., and Ruhnke M. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS 12 (1998) 2227-2228
13. Kartsonis N.A., Saah A., Lipka C.J., Taylor A., and Sable C.A. Second-line therapy with caspofungin for mucosal or invasive candidiasis: results from the caspofungin compassionate-use study. J Antimicrob Chemother 53 (2004) 878-881
14. Sora F., Chiusolo P., Piccirillo N., Pagano L., Laurenti L., Farina G., et al. Successful treatment with caspofungin of hepatosplenic candidiasis resistant to liposomal amphotericin B. Clin Infect Dis 35 (2002) 1135-1136
15. Cornely O.A., Lasso M., Betts R., Klimko N., Vazquez J., Dobb G., et al. Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother 60 (2007) 363-369
16. Kontny U., Walsh T.J., Rossler J., Uhl M., and Niemeyer C.M. Successful treatment of refractory chronic disseminated candidiasis after prolonged administration of caspofungin in a child with acute myeloid leukemia. Pediatr Blood Cancer 49 (2007) 360-362
17. Ostrosky-Zeichner L., Oude Lashof A.M., Kullberg B.J., and Rex J.H. Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 22 (2003) 651-655
18. Vehreschild J.J., Kruger K., Kurzai O., Wickenhauser C., Behringer K., Tox U., et al. Salvage therapy of refractory chronic disseminated candidiasis in a patient with acute myeloid leukaemia and secondary prophylaxis during allogeneic stem cell transplantation. Mycoses 49 Suppl 1 (2006) 42-47
19. De Pauw B.E., Raemaekers J.M., Donnelly J.P., Kullberg B.J., and Meis J.F. An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematological malignancy. Ann Hematol 70 (1995) 83-87
20. Anaissie E., Bodey G.P., Kantarjian H., David C., Barnett K., Bow E., et al. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 91 (1991) 142-150
21. Kauffman C.A., Bradley S.F., Ross S.C., and Weber D.R. Hepatosplenic candidiasis: successful treatment with fluconazole. Am J Med 91 (1991) 137-141
22. Sallah S., Semelka R.C., Wehbie R., Sallah W., Nguyen N.P., and Vos P. Hepatosplenic candidiasis in patients with acute leukaemia. Br J Haematol 106 (1999) 697-701
23. Kontoyiannis D.P., Luna M.A., Samuels B.I., and Bodey G.P. Hepatosplenic candidiasis. A manifestation of chronic disseminated candidiasis. Infect Dis Clin North Am 14 (2000) 721-739
24. Wong-Beringer A., Jacobs R.A., and Guglielmo B.J. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 27 (1998) 603-618
25. Sallah S., Semelka R.C., Sallah W., Vainright J.R., and Philips D.L. Amphotericin B lipid complex for the treatment of patients with acute leukemia and hepatosplenic candidiasis. Leuk Res 23 (1999) 995-999
26. Walsh T.J., Whitcomb P., Piscitelli S., Figg W.D., Hill S., Chanock S.J., et al. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob Agents Chemother 41 (1997) 1944-1948
27. Cornely O.A., Lasso M., Betts R., Klimko N., Vazquez J., Dobb G., et al. Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother 60 (2007) 363-369
28. Walsh T.J., Whitcomb P.O., Revankar S.G., and Pizzo P.A. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer 76 (1995) 2357-2362
29. Bjerke J.W., Meyers J.D., and Bowden R.A. Hepatosplenic candidiasis-a contraindication to marrow transplantation?. Blood 84 (1994) 2811-2814
30. Morrell M., Fraser V.J., and Kollef M.H. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 49 (2005) 3640-3645
31. Garey K.W., Rege M., Pai M.P., Mingo D.E., Suda K.J., Turpin R.S., et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 43 (2006) 25-31
32. Parkins M.D., Sabuda D.M., Elsayed S., and Laupland K.B. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 60 (2007) 613-618
33. Anaissie E.J., Rex J.H., Uzun O., and Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med 104 (1998) 238-245
34. Cuenca-Estrella M., Gomez-Lopez A., Mellado E., Buitrago M.J., Monzon A., and Rodriguez-Tudela J.L. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 50 (2006) 917-921
35. Almirante B., Rodriguez D., Park B.J., Cuenca-Estrella M., Planes A.M., Almela M., et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003. J Clin Microbiol 43 (2005) 1829-1835
36. Pfaller M.A., Diekema D.J., Rinaldi M.G., Barnes R., Hu B., Veselov A.V., et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-Year Analysis of Susceptibilities of Candida and Other Yeast Species to Fluconazole and Voriconazole by Standardized Disk Diffusion Testing. J Clin Microbiol 43 (2005) 5848-5859
37. Pfaller M.A., Messer S.A., Boyken L., Rice C., Tendolkar S., Hollis R.J., et al. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. tested by clinical and laboratory standards institute-recommended broth microdilution methods. J Clin Microbiol 45 (2007) 70-75
38. Panackal A.A., Gribskov J.L., Staab J.F., Kirby K.A., Rinaldi M., and Marr K.A. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol 44 (2006) 1740-1743
39. Alexander B.D., Schell W.A., Miller J.L., Long G.D., and Perfect J.R. Candida glabrata: fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation 80 (2005) 868-871
40. Pfaller M.A., Diekema D.J., and Sheehan D.J. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 19 (2006) 435-447
41. Rodriguez-Tudela J.L., Almirante B., Rodriguez-Pardo D., Laguna F., Donnelly J.P., Mouton J.W., et al. Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob Agents Chemother 51 (2007) 3599-3604
42. Pfaller M.A., Boyken L., Hollis R.J., Messer S.A., Tendolkar S., and Diekema D.J. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol 44 (2006) 760-763
43. Pfaller M.A., and Diekema D.J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20 (2007) 133-163
44. Lewis R.E. Pharmacodynamic implications for use of antifungal agents. Curr Opin Pharmacol 7 (2007) 491-497
45. Mora-Duarte J., Betts R., Rotstein C., Colombo A.L., Thompson-Moya L., Smietana J., et al. Comparison of caspofungin and amphotericin b for invasive candidiasis. N Engl J Med 347 (2002) 2020-2029
46. Reboli A.C., Rotstein C., Pappas P.G., Chapman S.W., Kett D.H., Kumar D., et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 356 (2007) 2472-2482
47. Kuse E.R., Chetchotisakd P., Da Cunha C.A., Ruhnke M., Barrios C., Raghunadharao D., et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369 (2007) 1519-1527
48. Pappas P.G., Rotstein C.M.F., Betts R.F., Nucci M., Talwar D., De Waele J.J., et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 45 (2007) 883-893
49. Lewis R.E., and Wiederhold N.P. The solubility ceiling: a rationale for continuous infusion amphotericin B therapy?. Clin Infect Dis 37 (2003) 871-872
50. Lewis R.E., Wiederhold N.P., Prince R.A., and Kontoyiannis D.P. In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin. J Antimicrob Chemother 57 (2006) 288-293
51. Eriksson U., Seifert B., and Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled. BMJ 322 (2001) 579-582
52. Altmannsberger P., Holler E., Andreesen R., and Krause S.W. Amphotericin B deoxycholate: no significant advantage of a 24 h over a 6 h infusion schedule. J Antimicrob Chemother 60 (2007) 180-182
53. Peleg A.Y., and Woods M.L. Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients. J Antimicrob Chemother 54 (2004) 803-808
54. Imhof A., Walter R.B., and Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis 36 (2003) 943-951
55. Andes D. Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin North Am 20 (2006) 679-697
56. Horn R., Wong B., Kiehn T.E., and Armstrong D. Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Rev Infect Dis 7 (1985) 646-655
57. Rex J.H., Bennett J.E., Sugar A.M., Pappas P.G., Van der Horst C.M., Edwards J.E., et al. A randomized trial comparing fluconazole with amphotericin b for the treatment of candidemia in patients without neutropenia. N Engl J Med 331 (1994) 1325-1330
58. Anaissie E.J., Darouiche R.O., Abi-Said D., Uzun O., Mera J., Gentry L.O., et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 23 (1996) 964-972
59. Phillips P., Shafran S., Garber G., Rotstein C., Smaill F., Fong I., et al., Canadian Candidemia Study Group. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Eur J Clin Microbiol Infect Dis 16 (1997) 337-345
60. Nguyen M.H., Peacock Jr. J.E., Tanner D.C., Morris A.J., Nguyen M.L., Snydman D.R., et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med 155 (1995) 2429-2435
61. Rex J.H., Pappas P.G., Karchmer A.W., Sobel J., Edwards J.E., Hadley S., et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 36 (2003) 1221-1228
62. Kullberg B.J., Sobel J.D., Ruhnke M., Pappas P.G., Viscoli C., Rex J.H., et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366 (2005) 1435-1442
63. Pachl J., Svoboda P., Jacobs F., Vandewoude K., Hoven B., Spronk P., et al. A randomized, blinded, multicenter trial of lipid-associated amphotericin b alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 42 (2006) 1404-1413
64. Shorr A.F., Lazarus D.R., Sherner J.H., Jackson W.L., Morrel M., Fraser V.J., et al. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia. Crit Care Med 35 (2007) 1077-1083
65. Lin M.Y., Carmeli Y., Zumsteg J., Flores E.L., Tolentino J., Sreeramoju P., et al. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob Agents Chemother 49 (2005) 4555-4560
66. Groll A.H., Giri N., Petraitis V., Petraitiene R., Candelario M., Bacher J.S., et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 182 (2000) 274-282
67. Lutsar I., Roffey S., and Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 37 (2003) 728-732
68. Bekersky I., Fielding R.M., Dressler D.E., Lee J.W., Buell D.N., and Walsh T.J. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin b (AmBisome) and amphotericin b deoxycholate in humans. Antimicrob Agents Chemother 46 (2002) 828-833
69. Agustin J., Lacson S., Raffalli J., Aguero-Rosenfeld M.E., and Wormser G.P. Failure of a lipid amphotericin B preparation to eradicate candiduria: preliminary findings based on three cases. Clin Infect Dis 29 (1999) 686-687
70. Van Burik J.H., Leisenring W., Myerson D., Hackman R.C., Shulman H.M., Sale G.E., et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. Medicine (Baltimore) 77 (1998) 246-254
71. Cole G.T., Halawa A.A., and Anaissie E.J. The role of the gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside. Clin Infect Dis 22 Suppl 2 (1996) S73-S88
72. Fraser V.J., Jones M., Dunkel J., Storfer S., Medoff G., and Dunagan W.C. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 15 (1992) 414-421
73. Nucci M., and Anaissie E. Should vascular catheters be removed from all patients with candidemia? An evidence-based review. Clin Infect Dis 34 (2002) 591-599
74. Anaissie E.J., Rex J.H., Uzun O., and Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med 104 (1998) 238-245
75. Kojic E.M., and Darouiche R.O. Candida infections of medical devices. Clin Microbiol Rev 17 (2004) 255-267
76. Denning D.W. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 23 (1996) 608-615
77. Patterson T.F., Kirkpatrick W.R., White M., Hiemenz J.W., Wingard J., DuPont B., et al., I3 Aspergillus Study Group. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. Medicine (Baltimore) 79 (2000) 250-260
78. Lin S.J., Schranz J., and Teutsch S.M. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 32 (2001) 358-366
79. Chen K.Y., Ko S.C., Hsueh P.R., Luh K.T., and Yang P.C. Pulmonary fungal infection: emphasis on microbiological spectra, patient outcome, and prognostic factors. Chest 120 (2001) 177-184
80. Janssen J.J., Strack van Schijndel R.J., Van der Poest Clement E.H., Ossenkoppele G.J., Thijs L.G., and Huijgens P.C. Outcome of ICU treatment in invasive aspergillosis. Intensive Care Med 22 (1996) 1315-1322
81. Denning D.W. Invasive aspergillosis. Clin Infect Dis 26 (1998) 781-803
82. Greene R.E., Schlamm H.T., Oestmann J.W., Stark P., Durand C., Lortholary O., et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 44 (2007) 373-379
83. Diekema D.J., Messer S.A., Hollis R.J., Jones R.N., and Pfaller M.A. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 41 (2003) 3623-3626
84. Goodwin M.L., and Drew R.H. Antifungal serum concentration monitoring: an update. J Antimicrob Chemother 61 (2008) 17-25
85. Pascual A., Calandra T., Bolay S., Buclin T., Bille J., and Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 46 (2008) 201-211
86. Perea S., Gonzalez G., Fothergill A.W., Kirkpatrick W.R., Rinaldi M.G., and Patterson T.F. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 46 (2002) 3039-3041
87. Kirkpatrick W.R., Perea S., Coco B.J., and Patterson T.F. Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 46 (2002) 2564-2568
88. Cacciapuoti A., Halpern J., Mendrick C., Norris C., Patel R., and Loebenberg D. Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection. Antimicrob Agents Chemother 50 (2006) 2587-2590
89. Heyn K., Tredup A., Salvenmoser S., and Muller F.M. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. Antimicrob Agents Chemother 49 (2005) 5157-5159
90. Lewis R.E., and Kontoyiannis D.P. Micafungin in combination with voriconazole in Aspergillus species: a pharmacodynamic approach for detection of combined antifungal activity in vitro. J Antimicrob Chemother 56 (2005) 887-892
91. MacCallum D.M., Whyte J.A., and Odds F.C. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrob Agents Chemother 49 (2005) 3697-3701
92. Cuenca-Estrella M., Gomez-Lopez A., Garcia-Effron G., Alcazar-Fuoli L., Mellado E., Buitrago M.J., et al. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus. Antimicrob Agents Chemother 49 (2005) 1232-1235
93. Petraitis V., Petraitiene R., Sarafandi A.A., Kelaher A.M., Lyman C.A., Casler H.E., et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 187 (2003) 1834-1843
94. O'Shaughnessy E.M., Meletiadis J., Stergiopoulou T., Demchok J.P., and Walsh T.J. Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species. J Antimicrob Chemother 58 (2006) 1168-1176
95. Arikan S., Lozano-Chiu M., Paetznick V., and Rex J.H. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 46 (2002) 245-247
96. Olson J.A., Adler-Moore J.P., Smith P.J., and Proffitt R.T. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin b with caspofungin or micafungin. Antimicrob Agents Chemother 49 (2005) 4895-4902
97. Sionov E., Mendlovic S., and Segal E. Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis. J Infect 53 (2005) 131-139
98. Luque J.C., Clemons K.V., and Stevens D.A. Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob Agents Chemother 47 (2003) 1452-1455
99. Meletiadis J., Mouton J.W., Meis J.F., and Verweij P.E. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother 47 (2003) 106-117
100. Perea S., Gonzalez G., Fothergill A.W., Sutton D.A., and Rinaldi M.G. In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles. J Clin Microbiol 40 (2002) 1831-1833
101. Mosquera J., Sharp A., Moore C.B., Warn P.A., and Denning D.W. In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp. J Antimicrob Chemother 50 (2002) 189-194
102. Kontoyiannis D.P., Lewis R.E., Sagar N., May G., Prince R.A., and Rolston K.V. Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy. Antimicrob Agents Chemother 44 (2000) 2915-2918
103. Louie A., Liu W., Miller D.A., Sucke A.C., Liu Q.F., Drusano G.L., et al. Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans. Antimicrob Agents Chemother 43 (1999) 2831-2840
104. Kirkpatrick W.R., Coco B.J., and Patterson T.F. Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 50 (2006) 1567-1569
105. Maesaki S., Kohno S., Kaku M., Koga H., and Hara K. Effects of antifungal agent combinations administered simultaneously and sequentially against Aspergillus fumigatus. Antimicrob Agents Chemother 38 (1994) 2843-2845
106. Lewis R.E., Prince R.A., Chi J., and Kontoyiannis D.P. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 46 (2002) 3208-3214
107. Schaffner A., and Frick P.G. The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. J Infect Dis 151 (1985) 902-910
108. Schaffner A., and Bohler A. Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism. Mycoses 36 (1993) 421-424
109. Louie A., Kaw P., Banerjee P., Liu W., Chen G., and Miller M.H. Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis. Antimicrob Agents Chemother 45 (2001) 485-494
110. Bowden R., Chandrasekar P., White M.H., Li X., Pietrelli L., Gurwith M., et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 35 (2002) 359-366
111. Walsh T.J., Hiemenz J.W., Seibel N.L., Perfect J.R., Horwith G., Lee L., et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 26 (1998) 1383-1396
112. Coukell A.J., and Brogden R.N. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis. Drugs 55 (1998) 585-612
113. Cornely O.A., Maertens J., Bresnik M., Ebrahimi R., Ullmann A.J., Bouza E., et al. Liposomal amphotericin b as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad Trial). Clin Infect Dis 44 (2007) 1289-1297
114. Denning D.W., Lee J.Y., Hostetler J.S., Pappas P., Kauffman C.A., Dewsnup D.H., et al. NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. Am J Med 97 (1994) 135-144
115. Stevens D.A., and Lee J.Y. Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria. Arch Intern Med 157 (1997) 1857-1862
116. Caillot D., Bassaris H., McGeer A., Arthur C., Prentice H.G., Seifert W., et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 33 (2001) e83-e90
117. Ellis M., Spence D., De Pauw B., Meunier F., Marinus A., Collette L., et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 27 (1998) 1406-1412
118. Maertens J., Raad I., Petrikkos G., Boogaerts M., Selleslag D., Petersen F.B., et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39 (2004) 1563-1571
119. Kartsonis N.A., Saah A.J., Joy L.C., Taylor A.F., and Sable C.A. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J Infect 50 (2005) 196-205
120. Candoni A., Mestroni R., Damiani D., Tiribelli M., Michelutti A., Silvestri F., et al. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies. Eur J Haematol 75 (2005) 227-233
121. Denning D.W., Marr K.A., Lau W.M., Facklam D.P., Ratanatharathorn V., Becker C., et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 53 (2006) 337-349
122. Walsh T.J., Raad I., Patterson T.F., Chandrasekar P., Donowitz G.R., Graybill R., et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 44 (2007) 2-12
123. Denning D.W., Ribaud P., Milpied N., Caillot D., Herbrecht R., Thiel E., et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34 (2002) 563-571
124. Stone J.A., Holland S.D., Wickersham P.J., Sterrett A., Schwartz M., Bonfiglio C., et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 46 (2002) 739-745
125. Walsh T.J., Goodman J.L., Pappas P., Bekersky I., Buell D.N., Roden M., et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 45 (2001) 3487-3496
126. Safdar A., Rodriguez G., Rolston K.V.I., O'brien S., Khouri I.F., Shpall E.J., et al. High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. Bone Marrow Transplant 39 (2007) 157-164
127. Aliff T.B., Maslak P.G., Jurcic J.G., Heaney M.L., Cathcart K.N., Sepkowitz K.A., et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 97 (2003) 1025-1032
128. Nivoix Y., Zamfir A., Lutun P., Kara F., Remy V., Lioure B., et al. Combination of caspofungin and an azole or an amphotericin B formulation in invasive fungal infections. J Infect 52 (2006) 67-74
129. Kontoyiannis D.P., Hachem R., Lewis R.E., Rivero G.A., Torres H.A., Thornby J., et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 98 (2003) 292-299
130. Cesaro S., Toffolutti T., Messina C., Calore E., Alaggio R., Cusinato R., et al. Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis. Eur J Haematol 73 (2004) 50-55
131. Marr K.A., Boeckh M., Carter R.A., Kim H.W., and Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 39 (2004) 797-802
132. Raad II, Hachem R, Jiang Y, Kantarjian H, Champlin R, Kontoyiannis D, et al. Combination salvave therapy of invasive aspergillosis (IA) in a patients with hematologic malignancy (HM): which caspofungin-containing regimen? 47th ICAAC 2007; Chicago, September 17-20, 2007.
133. Sutton D.A., Sanche S.E., Revankar S.G., Fothergill A.W., and Rinaldi M.G. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol 37 (1999) 2343-2345
134. Lass-Florl C., Griff K., Mayr A., Petzer A., Gastl G., Bonatti H., et al. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol 131 (2005) 201-207
135. Lass-Florl C., Kofler G., Kropshofer G., Hermans J., Kreczy A., Dierich M.P., et al. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother 42 (1998) 497-502
136. Schwartz S., Milatovic D., and Thiel E. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br J Haematol 97 (1997) 663-665
137. Schwartz S., Ruhnke M., Ribaud P., Corey L., Driscoll T., Cornely O.A., et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 106 (2005) 2641-2645
138. Nesky M.A., McDougal E.C., and Peacock Jr. J.E. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis. Clin Infect Dis 31 (2000) 673-677
139. Sharkey P.K., Graybill J.R., Johnson E.S., Hausrath S.G., Pollard R.B., Kolokathis A., et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 22 (1996) 315-321
140. Leenders A.C., Reiss P., Portegies P., Clezy K., Hop W.C., Hoy J., et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 11 (1997) 1463-1471
141. Caillot D., Couaillier J.F., Bernard A., Casasnovas O., Denning D.W., Mannone L., et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 19 (2001) 253-259
142. Petraitis V., Petraitiene R., Solomon J., Kelaher A.M., Murray H.A., Mya-San C., et al. Multidimensional volumetric imaging of pulmonary infiltrates for measuring therapeutic response to antifungal therapy in experimental invasive pulmonary aspergillosis. Antimicrob Agents Chemother 50 (2006) 1510-1517
143. Boutboul F., Alberti C., Leblanc T., Sulahian A., Gluckman E., Derouin F., et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis 34 (2002) 939-943
144. Becker M.J., Lugtenburg E.J., Cornelissen J.J., Van Der S.C., Hoogsteden H.C., and De Marie S. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol 121 (2003) 448-457
145. El Saleeby C.M., Allison K.J., Knapp K.M., Walsh T.J., and Hayden R.T. Discordant rise in galactomannan antigenemia in a patient with resolving aspergillosis, renal failure, and ongoing hemodialysis. J Clin Microbiol 43 (2005) 3560-3563
146. Petraitiene R., Petraitis V., Groll A.H., Sein T., Schaufele R.L., Francesconi A., et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 46 (2002) 12-23
147. Klont R.R., Mennink-Kersten M.A., Ruegebrink D., Rijs A.J., Blijlevens N.M., Donnelly J.P., et al. Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis. Clin Infect Dis 43 (2006) e23-e25
148. Maertens J., Glasmacher A., Selleslag D., Ngai A., Ryan D., Layton M., et al. Evaluation of serum sandwich enzyme-linked immunosorbent assay for circulating galactomannan during caspofungin therapy: results from the caspofungin invasive aspergillosis study. Clin Infect Dis 41 (2005) e9-14
149. Marr K.A., Balajee S.A., McLaughlin L., Tabouret M., Bentsen C., and Walsh T.J. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 190 (2004) 641-649
150. Berenguer J., Allende M.C., Lee J.W., Garrett K., Lyman C., Ali N.M., et al. Pathogenesis of pulmonary aspergillosis. Granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression. Am J Respir Crit Care Med 152 (1995) 1079-1086
151. Sulahian A., Boutboul F., Ribaud P., Leblanc T., Lacroix C., and Derouin F. Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study. Cancer 91 (2001) 311-318
152. Verweij P.E., Weemaes C.M., Curfs J.H., Bretagne S., and Meis J.F. Failure to detect circulating Aspergillus markers in a patient with chronic granulomatous disease and invasive aspergillosis. J Clin Microbiol 38 (2000) 3900-3901
153. Aquino V.R., Goldani L.Z., and Pasqualotto A.C. Update on the contribution of galactomannan for the diagnosis of invasive aspergillosis. Mycopathologia 163 (2007) 191-202
154. Marr K.A., Laverdiere M., Gugel A., and Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 40 (2005) 1762-1769
155. Herbrecht R., Letscher-Bru V., Oprea C., Lioure B., Waller J., Campos F., et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 20 (2002) 1898-1906
156. Machetti M., Furfaro E., and Viscoli C. Galactomannan in piperacillin-tazobactam: how much and to what extent?. Antimicrob Agents Chemother 49 (2005) 3984-3985
157. Viscoli C., Machetti M., Cappellano P., Bucci B., Bruzzi P., Van Lint M.T., et al. False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis 38 (2004) 913-916
158. Adam O., Auperin A., Wilquin F., Bourhis J.H., Gachot B., and Chachaty E. Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clin Infect Dis 38 (2004) 917-920
159. Bart-Delabesse E., Basile M., Al Jijakli A., Souville D., Gay F., Philippe B., et al. Detection of Aspergillus galactomannan antigenemia to determine biological and clinical implications of beta-lactam treatments. J Clin Microbiol 43 (2005) 5214-5220
160. Singh N., Obman A., Husain S., Aspinall S., Mietzner S., and Stout J.E. Reactivity of platelia Aspergillus galactomannan antigen with piperacillin-tazobactam: clinical implications based on achievable concentrations in serum. Antimicrob Agents Chemother 48 (2004) 1989-1992
161. Aubry A., Porcher R., Bottero J., Touratier S., Leblanc T., Brethon B., et al. Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders. J Clin Microbiol 44 (2006) 389-394
162. Walsh T.J., Shoham S., Petraitiene R., Sein T., Schaufele R., Kelaher A., et al. Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction. J Clin Microbiol 42 (2004) 4744-4748
163. Maertens J., Van Eldere J., Verhaegen J., Verbeken E., Verschakelen J., and Boogaerts M. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 186 (2002) 1297-1306
164. Kwa A.L., Loh C., Low J.G., Kurup A., and Tam V.H. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 41 (2005) 754-757
165. Busca A., Locatelli F., Barbui A., Limerutti G., Serra R., Libertucci D., et al. Usefulness of sequential Aspergillus galactomannan antigen detection combined with early radiologic evaluation for diagnosis of invasive pulmonary aspergillosis in patients undergoing allogeneic stem cell transplantation. Transplant Proc 38 (2006) 1610-1613
166. Pickering J.W., Sant H.W., Bowles C.A., Roberts W.L., and Woods G.L. Evaluation of a (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol. 43 (2005) 5957-5962
167. Maertens J., Theunissen K., Verbeken E., Lagrou K., Verhaegen J., Boogaerts M., et al. Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 126 (2004) 852-860
168. Boogaerts M., Winston D.J., Bow E.J., Garber G., Reboli A.C., Schwarer A.P., et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 135 (2001) 412-422
169. Pizzo P.A., Robichaud K.J., Gill F.A., and Witebsky F.G. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 72 (1982) 101-111
170. EORTC, International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 86 (1989) 668-672
171. Walsh T.J., Finberg R.W., Arndt C., Hiemenz J., Schwartz C., Bodensteiner D., et al., National Institute of Allergy and Infectious Diseases Mycoses Study Group. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 340 (1999) 764-771
172. Morgenstern G.R., Prentice A.G., Prentice H.G., Ropner J.E., Schey S.A., Warnock D.W., and UK Multicentre Antifungal Prophylaxis Study Group. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. Br J Haematol 105 (1999) 901-911
173. Wingard J.R., White M.H., Anaissie E., Raffalli J., Goodman J., Arrieta A., and L Amph/ABLC Collaborative Study Group. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 31 (2000) 1155-1163
174. Winston D.J., Hathorn J.W., Schuster M.G., Schiller G.J., and Territo M.C. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 108 (2000) 282-289
175. Malik I.A., Moid I., Aziz Z., Khan S., and Suleman M. A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. Am J Med 105 (1998) 478-483
176. Walsh T.J., Pappas P., Winston D.J., Lazarus H.M., Petersen F., Raffalli J., et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346 (2002) 225-234
177. Walsh T.J., Teppler H., Donowitz G.R., Maertens J.A., Baden L.R., Dmoszynska A., et al. Caspofungin versus liposomal amphotericin b for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351 (2004) 1391-1402
178. Zelenitsky S.A., Iacovides H., Ariano R.E., and Harding G.K. Antibiotic combinations significantly more active than monotherapy in an in vitro infection model of Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 51 (2005) 39-43
179. Bates D.W., Su L., Yu D.T., Chertow G.M., Seger D.L., Gomes D.R., et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 32 (2001) 686-693
180. Harousseau J.L., Dekker A.W., Stamatoullas-Bastard A., Fassas A., Linkesch W., Gouveia J., et al. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother 44 (2000) 1887-1893
181. Winston D.J., Maziarz R.T., Chandrasekar P.H., Lazarus H.M., Goldman M., Blumer J.L., et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: a multicenter, randomized trial. Ann Intern Med 138 (2003) 705-713
182. Nucci M., Biasoli I., Akiti T., Silveira F., Solza C., Barreiros G., et al. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin Infect Dis 30 (2000) 300-305
183. Menichetti F., Del Favero A., Martino P., Bucaneve G., Micozzi A., Girmenia C., et al., GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. Clin Infect Dis 28 (1999) 250-255
184. Cornely O.A., Maertens J., Winston D.J., Perfect J., Ullmann A.J., Walsh T.J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356 (2007) 348-359
185. Ullmann A.J., Lipton J.H., Vesole D.H., Chandrasekar P., Langston A., Tarantolo S.R., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356 (2007) 335-347
186. Marr K.A., and Leisenring W. Design issues in studies evaluating diagnostic tests for aspergillosis. Clin Infect Dis 41 Suppl 6 (2005) S381-S386
187. Pfeiffer C.D., Fine J.P., and Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 42 (2006) 1417-1727
188. Cagnoni P.J. Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Antimicrob Chemother 49 (2002) 81-86